These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9459393)

  • 1. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers.
    Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K; Martin S; Gotch F; Kingsman A
    Vaccine; 1995 Jun; 13(9):831-4. PubMed ID: 7483805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
    Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
    J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
    Benson EM; Clarkson J; Law M; Marshall P; Kelleher AD; Smith DE; Patou G; Stewart GJ; Cooper DA; French RA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):105-13. PubMed ID: 10029243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals.
    Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F
    AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
    Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
    Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.
    Smith D; Gow I; Colebunders R; Weller I; Tchamouroff S; Weber J; Boag F; Hales G; Adams S; Patou G; Cooper DA;
    HIV Med; 2001 Oct; 2(4):272-5. PubMed ID: 11737409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
    Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
    Slade H; Turner J; Abrams C; Carlo D; Salk J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
    [No Abstract]   [Full Text] [Related]  

  • 12. A 7-year analysis of anti-Gag (p17 and p24) antibodies in HIV-1-seropositive patients with haemophilia: immunoglobulin G titre and avidity are early predictors of clinical course.
    Chargelegue D; Colvin BT; O'Toole CM
    AIDS; 1993 Nov; 7 Suppl 2():S87-90. PubMed ID: 7909231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips".
    MacGregor RR; Boyer JD; Ugen KE; Tebas P; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; Weiner DB
    Vaccine; 2005 Mar; 23(17-18):2066-73. PubMed ID: 15755572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
    Turner JL; Trauger RJ; Daigle AE; Carlo DJ
    AIDS; 1994 Oct; 8(10):1429-35. PubMed ID: 7818813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
    Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.